Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab
and pembrolizumab, are associated with high response rates in patients with relapsed or …

Background CT and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT performances
following immune therapy are not well known in patients with relapsed or refractory Hodgkin …

The response evaluation criteria in patients with Hodgkin lymphoma (HL) were designed for
the assessment of chemotherapy and targeted molecular agents. We investigated the …

Purpose: A primary analysis of the ongoing NIVAHL trial demonstrated unexpectedly high
interim complete response rates to nivolumab-based first-line treatment in early-stage …

Our aim was to evaluate Hodgkin Lymphoma (HL) response to checkpoint inhibitors with
18F-FDG PET/CT. Forty three refractory or relapsed HL patients were investigated before …

Introduction: Genetic alterations at 9p24. 1 resulting in overexpression of programmed death-
1 (PD-1) ligands are near-universal in cHL (Roemer et al, J Clin Oncol 2016); cHL may thus …

Abstract Introduction: Classical Hodgkin lymphoma (cHL) is characterized by Reed
Sternberg (RS) cells surrounded by an extensive but ineffective inflammatory/immune cell …

Introduction: Nivolumab (nivo) is an anti-PD-1 antibody that restores effective anti-tumor
immune responses and is tolerable and effective in patients (pts) with relapsed/refractory …

Abstract Introduction: The programmed death-1 (PD-1) immune checkpoint pathway
regulates T-cell-mediated antitumor immune responses in solid tumors and hematologic …

The paradigm of response in Hodgkin lymphoma (HL) was developed in cytotoxic
chemotherapies and its use as a reference model for immune-modulatory regimens, which …